CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 189 enrolled
Drug / intervention
Efalizumabdrug
Likely dose
Efalizumab 0.7 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00287118
NCT00287118Phase 4Completed
CompareCT.gov

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

Merck KGaA, Darmstadt, Germany·interventional·Posted Feb 6, 2006·Updated Apr 3, 2018

In Brief

A Phase 4 clinical trial evaluating Efalizumab for Candidates for Systemic Therapy for Psoriasis and Psoriasis. Completed, enrolled 189 participants across 1 site.

Detailed Summary

An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCandidates for Systemic Therapy for Psoriasis, Psoriasis
CountriesSwitzerland
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2006
Enrollment StartOct 27, 2004
Primary CompletionMay 30, 2006
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 20.4 years ago

Interventions

Efalizumabdrug

Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.